Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients

World Journal of Gastroenterology

Volumn 22, Issue 9, 2016, Pages 2749-2759

  Gu, Xiang Qian ^a   Zheng, Wei Ping ^b   Teng, Da Hong ^b   Sun, Ji San ^b   Zheng, Hong ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Deceased donor; Hepatocellular carcinoma; Immunosuppressive agents; Liver transplantation; Living donor; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; IMMUNOSUPPRESSIVE AGENT;

ALPHA FETOPROTEIN BLOOD LEVEL; CANCER IMMUNOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; GRAFT RECIPIENT; HEPATITIS VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; RISK REDUCTION; TUMOR INVASION; TUMOR RECURRENCE; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; COMPLICATION; HEPATITIS B; HEPATITIS C; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; COMORBIDITY; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84959862876     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i9.2749     Document Type: Review

References (112)

1. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013; 26: 109-118 [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x]
2. Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007; 12: 527-534 [PMID: 18024261]
3. PiarDi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, Marzano E, Audet M, Wolf P, Pessaux P. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 2020-2026 [PMID: 22179632 DOI: 10.1245/s10434-011-2170-9]
4. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, Paraskevas S, Hassanain M, Tchervenkov JI. Pretransplantation fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013; 95: 228-233 [PMID: 23222895 DOI: 10.1097/TP.0b013e31827743d7]
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/nejm199603143341104]
6. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
7. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]
8. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732 [PMID: 18580463 DOI: 10.1097/TP.0b013e31816b67e4]
9. Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, OdalDi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol 2013; 19: 9174-9182 [PMID: 24409045 DOI: 10.3748/wjg.v19.i48.9174]
10. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]
11. Yan S, Ding Y, Tian Y, Lu Z, Wang Y, Zhang Q, Ye Y, Zhou L, Xie H, Chen H, Zheng M, Zheng S. MHC-mismatched mice liver transplantation promotes tumor growth in liver graft. Cancer Lett 2014; 351: 162-171 [PMID: 24880081 DOI: 10.1016/j.canlet.2014.05.010]
12. Yang L. TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. Curr Mol Med 2010; 10: 374-380 [PMID: 20455854 DOI: 10.2174/15665241079 1317039]
13. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005; 11: 267-280 [PMID: 15719409 DOI: 10.1002/lt.20373]
14. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181896278]
15. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751 [PMID: 12499891 DOI: 10.1097/01. TP.0000039170.17434.33]
16. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, BolonDi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503 [PMID: 15838913 DOI: 10.1002/lt.20391]
17. Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol 2012; 56: 176-183 [PMID: 21835141 DOI: 10.1016/j.jhep.2011.07.013]
18. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983.e1-11 [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008]
19. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135 [PMID: 11821896 DOI: 10.1038/nm0202-128]
20. Guba M, Graeb C, Jauch KW, Geissler EK. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-1782 [PMID: 15223891]
21. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]
22. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24943720 DOI: 10.1111/tri.12372]
23. Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, Wang Z, Dai Z, Tang ZY, Zhou J. An immune function assay predicts posttransplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 1445-1453 [PMID: 21809031 DOI: 10.1007/s00432-011-1014-0]
24. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2014; 97: 694-701 [PMID: 24637868 DOI: 10.1097/01.TP.0000437426.15890.1d]
25. Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Dal Maso L, Ballarini P, Pezzotti P, Smacchia C, Pesce A, Ippolito G, Franceschi S, Rezza G. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14: 553-559 [PMID: 10780718 DOI: 10.1097/00002030-200003310-00011]
26. Altavilla G, Caputo A, LanfreDi M, Piola C, Barbanti-Brodano G, Corallini A. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157: 1081-1089 [PMID: 11021811 DOI: 10.1016/S0002-9440(10)64622-6]
27. Berretta M, Garlassi E, Cacopardo B, Cappellani A, GuaralDi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A, Di Gangi P, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16: 1258-1269 [PMID: 21868692 DOI: 10.1634/theoncologist.2010-0400]
28. Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, De Ruvo N, Berretta M, Adani GL, Zanello M, Tavio M, Cautero N, Tirelli U, Pinna AD, Gerunda GE, GuaralDi G. Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist 2013; 18: 592-599 [PMID: 23666950 DOI: 10.1634/theoncologist.2012-0255]
29. Vibert E, Duclos-Vallée JC, Ghigna MR, Hoti E, Salloum C, Guettier C, Castaing D, Samuel D, Adam R. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology 2011; 53: 475-482 [PMID: 21274869 DOI: 10.1002/hep.24062]
30. Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant 2012; 26: E359-E364 [PMID: 22693962 DOI: 10.1111/j.1399-0012.2012.01668.x]
31. Bittermann T, Niu B, Hoteit MA, Goldberg D. Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach. Am J Transplant 2014; 14: 79-87 [PMID: 24304509 DOI: 10.1111/ajt.12530]
32. Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, Hong G, Yi NJ, Kwon CH, Joh JW, Lee SK, Suh KS. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014; 97: 71-77 [PMID: 24056623 DOI: 10.1097/TP.0b013e3182a68953]
33. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant 2013; 27: 140-147 [PMID: 23157398 DOI: 10.1111/ctr.12031]
34. Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15: 1861-1866 [PMID: 19938113 DOI: 10.1002/lt.21940]
35. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94: 78-86 [PMID: 17016793 DOI: 10.1002/bjs.5528]
36. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, Cheng Q, Sun CK, Fan ST. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008; 247: 1049-1057 [PMID: 18520234 DOI: 10.1097/SLA.0b013e31816ffab6XXX]
37. Shi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 2011; 17: 866-874 [PMID: 21542129 DOI: 10.1002/lt.22325]
38. Yang ZF, Poon RT, Luo Y, Cheung CK, Ho DW, Lo CM, Fan ST. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol 2004; 173: 2507-2515 [PMID: 15294966 DOI: 10.4049/jimmunol.173.4.2507]
39. Man K, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, Lee TK, Tsui SH, Ng IO, Zhang ZW, Wong J. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003; 237: 256-264 [PMID: 12560784 DOI: 10.1097/01.SLA.0000048976.11824.67]
40. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: S277-S282 [PMID: 15508095 DOI: 10.1007/978-1-60327-376-3-19]
41. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608 [PMID: 17511683 DOI: 10.1111/j.1600-6143.2007.01802.x]
42. Di Sandro S, Slim AO, Giacomoni A, Lauterio A, Mangoni I, Aseni P, Pirotta V, Aldumour A, Mihaylov P, De Carlis L. Living donor liver transplantation for hepatocellular carcinoma: longterm results compared with deceased donor liver transplantation. Transplant Proc 2009; 41: 1283-1285 [PMID: 19460539 DOI: 10.1016/j.transproceed.2009.03.022]
43. Xiao GQ, Song JL, Shen S, Yang JY, Yan LN. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol 2014; 20: 10953-10959 [PMID: 25152599 DOI: 10.3748/wjg.v20.i31.10953]
44. Sandhu L, Sandroussi C, Guba M, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Levy G, Greig PD, Renner EL, Grant DR. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012; 18: 315-322 [PMID: 22140013 DOI: 10.1002/lt.22477]
45. Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D. Intention-totreat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011; 53: 1570-1579 [PMID: 21520172 DOI: 10.1002/hep.24231]
46. Khan S, Silva MA, Tan YM, John A, Gunson B, Buckels JA, David Mayer A, Bramhall SR, Mirza DF. Conventional versus piggyback technique of caval implantation; without extra-corporeal venovenous bypass. A comparative study. Transpl Int 2006; 19: 795-801 [PMID: 16961770 DOI: 10.1111/j.1432-2277.2006.00331.x]
47. Gr?t M, Kornasiewicz O, Lewandowski Z, Skalski M, Zieniewicz K, P?czek L, Krawczyk M. The impact of surgical technique on the results of liver transplantation in patients with hepatocellular carcinoma. Ann Transplant 2013; 18: 448-459 [PMID: 24008493 DOI: 10.12659/AOT.884005]
48. Mangus RS, Fridell JA, Vianna RM, Cooper AB, Jones DT, Tector AJ. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation 2008; 85: 1496-1499 [PMID: 18497692 DOI: 10.1097/TP.0b013e31816feec0]
49. Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]
50. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-321 [PMID: 7843699 DOI: 10.1016/0270-9139(95)90086-1]
51. Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol 2013; 19: 8895-8901 [PMID: 24379613 DOI: 10.3748/wjg.v19.i47.8895]
52. Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19: 8861-8866 [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861]
53. Li MR, Chen GH, Cai CJ, Wang GY, Zhao H. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion 2011; 84: 134-141 [PMID: 21502763 DOI: 10.1159/000324197]
54. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534 [PMID: 19877207 DOI: 10.1002/lt.21882]
55. Lai Q, Avolio AW, Lerut J, Singh G, Chan SC, Berloco PB, Tisone G, Agnes S, Chok KS, Sharr W, Rossi M, Manzia TM, Lo CM. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol 2012; 57: 974-979 [PMID: 22771712 DOI: 10.1016/j.jhep.2012.06.033]
56. Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, Yeh CT, Lee WC. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol 2013; 20: 3582-3590 [PMID: 23760589 DOI: 10.1245/s10434-013-3023-5]
57. Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int 2012; 25: 192-200 [PMID: 22151471 DOI: 10.1111/j.1432-2277.2011.01396.x]
58. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD, Gornbein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619; discussion 619-620 [PMID: 11981206 DOI: 10.1097/00000658-20 0205000-00002]
59. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013; 15: 504-510 [PMID: 23750492 DOI: 10.1111/j.1477-2574.2012.00602.x]
60. Sweeney G. Leptin signalling. Cell Signal 2002; 14: 655-663 [PMID: 12020765 DOI: 10.1016/s0898-6568(02)00006-2]
61. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006; 207: 12-22 [PMID: 16110483 DOI: 10.1002/jcp.20472]
62. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007; 67: 2497-2507 [PMID: 17363567 DOI: 10.1158/0008-5472. CAN-06-3075]
63. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K, Wojta J. Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol 2007; 27: 1587-1595 [PMID: 17525365 DOI: 10.1161/atvbaha.107.143081]
64. Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, Jacobson JS, Hershman DL, Verna EC, Zaretsky J, Halazun K, Dove L, Brown RS, Neugut AI, Kato T, Remotti H, Coppleson YJ, Emond JC. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation 2012; 94: 539-543 [PMID: 22864187 DOI: 10.1097/TP.0b013e31825c58ea]
65. Taner CB, Ung RL, Rosser BG, Aranda-Michel J. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatol Int 2012; 6: 403-407 [PMID: 21688082 DOI: 10.1007/s12072-011-9286-7]
66. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvárez-Cienfuegos J, Prieto J. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003; 3: 1407-1412 [PMID: 14525602 DOI: 10.1046/j.1600-6143.2003.00227.x]
67. Malinis MF, Chen S, Allore HG, Quagliarello VJ. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era. Ann Transplant 2014; 19: 478-487 [PMID: 25256592 DOI: 10.12659/AOT.890934]
68. Martins PN, Pratschke J, Pascher A, Fritsche L, Frei U, Neuhaus P, Tullius SG. Age and immune response in organ transplantation. Transplantation 2005; 79: 127-132 [PMID: 15665758 DOI: 10.1097/01.tp.0000146258.79425.04]
69. Kim J, Ko ME, Nelson RA, Arrington A, Luu C, Falor AE, Nissen NN, Colquhoun S, Hurria A, Singh G. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg 2014; 218: 431-438 [PMID: 24559955 DOI: 10.1016/j.jamcollsurg.2013.12.001]
70. Ballarin R, Montalti R, Spaggiari M, Cautero N, De Ruvo N, Guerrini GP, Rompianesi G, Longo C, Gerunda GE, Di Benedetto F. Liver transplantation in older adults: our point of view. J Am Geriatr Soc 2011; 59: 1359-1361 [PMID: 21751978 DOI: 10.1111/j.1532-5415.2011.03462.x]
71. Adani GL, Baccarani U, Lorenzin D, Rossetto A, Nicolini D, Vecchi A, De Luca S, Risaliti A, De Anna D, Bresadola F, Bresadola V. Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41: 1293-1294 [PMID: 19460542 DOI: 10.1016/j.transproceed.2009.03.080]
72. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124 [PMID: 17615358 DOI: 10.1126/science.1140485]
73. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer 2014; 120: 3707-3716 [PMID: 25081299 DOI: 10.1002/cncr.28912]
74. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015; 61: 895-904 [PMID: 25099130 DOI: 10.1002/hep.27358]
75. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IH. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175 [PMID: 15962318 DOI: 10.1002/hep.20739]
76. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT, Fan ST. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases-activation of cell invasion and migration pathways. Liver Transpl 2007; 13: 1669-1677 [PMID: 18044786 DOI: 10.1002/lt.21193]
77. Ku Y, Kusunoki N, Shiotani M, Maeda I, Iwasaki T, Tominaga M, Kitagawa T, Fukumoto T, Suzuki Y, Kuroda Y. Stimulation of haematogenous liver metastases by ischaemia-reperfusion in rats. Eur J Surg 1999; 165: 801-807 [PMID: 10494650 DOI: 10.1080/1 1024159950189627]
78. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47 [PMID: 11902584 DOI: 10.1038/nrc704]
79. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490 [PMID: 9697772 DOI: 10.1038/28867]
80. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93: E73-E80 [PMID: 16935775 DOI: 10.1158/0008-5472. can-04-2184]
81. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005; 16: 554-563 [PMID: 16144692 DOI: 10.1016/j.semcdb.2005.03.007]
82. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013; 19: 1214-1223 [PMID: 23907778 DOI: 10.1002/lt.23715]
83. Gasbarrini A, Addolorato G, Di Campli C, Simoncini M, Montemagno S, Castagneto M, Padalino C, Pola P, Gasbarrini G. Gender affects reperfusion injury in rat liver. Dig Dis Sci 2001; 46: 1305-1312 [PMID: 11414309]
84. Wittnich C, Belanger MP, Askin N, Boscarino C, Wallen WJ. Lower liver transplant success in females: gender differences in metabolic response to global ischemia. Transplant Proc 2004; 36: 1485-1488 [PMID: 15251365 DOI: 10.1016/j.transproceed.2004.0 5.055]
85. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012; 57: 806-812 [PMID: 21953139 DOI: 10.1007/s10620-011-1910-9]
86. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, Zimmerman M, Hong J, Collins TE, Gornbein J, Amersi F, Weaver M, Cao C, Chen T, Hiatt JR, Busuttil RW. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006; 243: 748-753; discussion 753-755 [PMID: 16772778 DOI: 10.1097/01.sla.0000219669.84192.b3]
87. Segev DL, Maley WR, Simpkins CE, Locke JE, Nguyen GC, Montgomery RA, Thuluvath PJ. Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology 2007; 46: 1907-1918 [PMID: 17918247 DOI: 10.1002/hep.21888]
88. Pagano D, Grosso G, Vizzini G, Spada M, Cintorino D, Malaguarnera M, Donati M, Mistretta A, Gridelli B, Gruttadauria S. Recipient-donor age matching in liver transplantation: a singlecenter experience. Transplant Proc 2013; 45: 2700-2706 [PMID: 24034027 DOI: 10.1016/j.transproceed.2013.07.039]
89. Lo CM, Shaked A, Busuttil RW. Risk factors for liver transplantation across the ABO barrier. Transplantation 1994; 58: 543-547 [PMID: 8091480 DOI: 10.1097/00007890-199409150-00 003]
90. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336: 519-523 [PMID: 1975036 DOI: 10.1016/0140-6736(90)92082-s]
91. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, Iguchi T, Hashimoto N, Maehara Y. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009; 88: 303-307 [PMID: 19667930 DOI: 10.1097/TP.0b013e3181adcae6]
92. Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, Petruccelli S, Morelli L, Campani D, Pollina L, Biancofiore G, BinDi L, Tascini C, Menichetti F, Scatena F, Filipponi F. The role of immunomodulation in ABOincompatible adult liver transplant recipients. J Clin Apher 2008; 23: 55-62 [PMID: 18186527 DOI: 10.1002/jca.20156]
93. Lee SD, Kim SH, Kong SY, Kim YK, Park SJ. Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transpl Immunol 2015; 32: 29-34 [PMID: 25449537 DOI: 10.1016/j.trim.2014.11.216]
94. Miyagi S, Kawagishi N, Sekiguchi S, Akamatsu Y, Sato K, Takeda I, Kobayashi Y, Tokodai K, Fujimori K, Satomi S. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2012; 44: 797-801 [PMID: 22483499 DOI: 10.1016/j.transproceed .2012.01.012]
95. Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F, Wisse E. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002; 72: 668-676 [PMID: 12377935]
96. Teng da H, Zhu ZJ, Zheng H, Deng YL, Sun LY, Pan C, Liu YH, Song HL, Shen ZY. Effect of steatosis donor liver transplantation on hepatocellular carcinoma recurrence: experience at a single institution. Hepatogastroenterology 2012; 59: 858-862 [PMID: 22389257 DOI: 10.5754/hge12007]
97. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113 [PMID: 11296690 DOI: 10.1055/s-2001-12933]
98. Ramachandran S, Liaw JM, Jia J, Glasgow SC, Liu W, Csontos K, Upadhya GA, Mohanakumar T, Chapman WC. Ischemiareperfusion injury in rat steatotic liver is dependent on NF?B P65 activation. Transpl Immunol 2012; 26: 201-206 [PMID: 22286145 DOI: 10.1016/j.trim.2012.01.001]
99. Tashiro H, Kuroda S, Mikuriya Y, Ohdan H. Ischemia-reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery. Surg Today 2014; 44: 1611-1625 [PMID: 24078000 DOI: 10.1007/s00595-013-0736-9]
100. Jiménez-Castro MB, Casillas-Ramírez A, Mendes-Braz M, Massip-Salcedo M, Gracia-Sancho J, Elias-Miró M, Rodés J, Peralta C. Adiponectin and resistin protect steatotic livers undergoing transplantation. J Hepatol 2013; 59: 1208-1214 [PMID: 23867317 DOI: 10.1016/j.jhep.2013.07.015]
101. Doyle MB, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, Brunt EM, Chapman WC. Short-and long-term outcomes after steatotic liver transplantation. Arch Surg 2010; 145: 653-660 [PMID: 20644128 DOI: 10.1001/archsurg.2010.119]
102. Schiergens TS, Rentsch M, Kasparek MS, Frenes K, Jauch KW, Thasler WE. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum 2015; 58: 74-82 [PMID: 25489697 DOI: 10.1097/DCR.0000000000000233]
103. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012; 256: 235-244 [PMID: 22791100 DOI: 10.1097/SLA.0b013e31825b35d5]
104. Dionigi G, Rovera F, Boni L, Carrafiello G, Recaldini C, Mangini M, Laganà D, Bacuzzi A, Dionigi R. The impact of perioperative blood transfusion on clinical outcomes in colorectal surgery. Surg Oncol 2007; 16 Suppl 1: S177-S182 [PMID: 18023576 DOI: 10.1016/j.suronc.2007.10.016]
105. Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA, Staley CA, Kooby DA. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol 2011; 18: 1327-1334 [PMID: 21369744 DOI: 10.1245/s10434-010-1476-3]
106. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther 2002; 9: 389-395 [PMID: 12237730 DOI: 10.1097/00045391-200209000-00005]
107. Innerhofer P, Tilz G, Fuchs D, Luz G, Hobisch-Hagen P, Schobersberger W, Nussbaumer W, Lochs A, Irschick E. Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus WBCreduced blood transfusions in patients undergoing arthroplasty. II. Activation of T cells, macrophages, and cell-mediated lympholysis. Transfusion 2000; 40: 821-827 [PMID: 10924610 DOI: 10.1046/j.153 7-2995.2000.40070821.x]
108. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999; 93: 1770-1777 [PMID: 10029607 DOI: 10.3109/104281900 09053536]
109. Waymack JP, Gallon L, Barcelli U, Trocki O, Alexander JW. Effect of blood transfusions on immune function. III. Alterations in macrophage arachidonic acid metabolism. Arch Surg 1987; 122: 56-60 [PMID: 3492188 DOI: 10.1001/archsurg.1987.01400130062009]
110. Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64: 308-310 [PMID: 6234037 DOI: 10.1378/chest.91.1.26]
111. Jubert AV, Lee ET, Hersh EM, McBride CM. Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence. J Surg Res 1973; 15: 399-403 [PMID: 4544256 DOI: 10.1016/0022-4804(73)90110-8]
112. Kaido T, Takada Y, Egawa H, Uemoto S. The influence of intraoperative homologous blood transfusion on prognosis after liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 808-812 [PMID: 19621707]